FDA Hopes to Enlist ABI, GE, Others to Help It Better Understand Microarrays | GenomeWeb

BOSTON — As the US Food and Drug Administration prepares to release its pharmacogenomic data-submissions guidelines on Friday, the agency has launched an initiative to gain microarray expertise by working closely with prominent players in the space.

Generally, the FDA has taken these steps to learn how pharmas may incorporate microarray data into drug discovery, to understand those data, and to become comfortable with them, according to several sources interviewed for this article.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.